146 related articles for article (PubMed ID: 30806569)
1. Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
Palmer AJ; van der Mei I; Taylor BV; Clarke PM; Simpson S; Ahmad H
Mult Scler; 2020 Apr; 26(4):411-420. PubMed ID: 30806569
[TBL] [Abstract][Full Text] [Related]
2. Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
Palmer AJ; Zhao T; Taylor BV; van der Mei I; Campbell JA
J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):401-409. PubMed ID: 37918903
[TBL] [Abstract][Full Text] [Related]
3. Modeling lifetime costs and health outcomes attributable to secondhand smoke exposure at home among Korean adult women.
Lee J; Han AR; Choi D; Lim KM; Bae S
BMJ Open; 2017 May; 7(5):e013292. PubMed ID: 28515183
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
5. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
[TBL] [Abstract][Full Text] [Related]
6. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
Brown LJ; Li J; Brunner M; Snoke M; La HA
J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
[TBL] [Abstract][Full Text] [Related]
7. The economic impact of multiple sclerosis in Australia in 2010.
Palmer AJ; Colman S; O'Leary B; Taylor BV; Simmons RD
Mult Scler; 2013 Oct; 19(12):1640-6. PubMed ID: 23652216
[TBL] [Abstract][Full Text] [Related]
8. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
[TBL] [Abstract][Full Text] [Related]
9. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
[TBL] [Abstract][Full Text] [Related]
10. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
11. Societal costs of multiple sclerosis in Ireland.
Carney P; O'Boyle D; Larkin A; McGuigan C; O'Rourke K
J Med Econ; 2018 May; 21(5):425-437. PubMed ID: 29320900
[TBL] [Abstract][Full Text] [Related]
12. Impact of overweight and obesity on life expectancy, quality-adjusted life years and lifetime costs in the adult population of Ghana.
Lartey S; Si L; Lung T; Magnussen CG; Boateng GO; Minicuci N; Kowal P; Hayes A; de Graaff B; Blizzard L; Palmer AJ
BMJ Glob Health; 2020 Sep; 5(9):. PubMed ID: 32994229
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
Nuijten MJ; Hutton J
Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
[TBL] [Abstract][Full Text] [Related]
14. Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure.
Gao L; Moodie M
BMJ Open; 2019 Sep; 9(9):e031033. PubMed ID: 31492790
[TBL] [Abstract][Full Text] [Related]
15. Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model.
de Graaff B; Si L; Neil AL; Yee KC; Sanderson K; Gurrin LC; Palmer AJ
Pharmacoecon Open; 2017 Mar; 1(1):37-51. PubMed ID: 29442300
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
18. Costs and quality of life in multiple sclerosis in The Netherlands.
Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
[TBL] [Abstract][Full Text] [Related]
19. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a.
Frasco MA; Shih T; Incerti D; Diaz Espinosa O; Vania DK; Thomas N
J Med Econ; 2017 Oct; 20(10):1074-1082. PubMed ID: 28726530
[TBL] [Abstract][Full Text] [Related]
20. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
